Ema committee for medicinal products for human use adopts positive opinion recommending authorization of moderna's omicron ba.4-ba.5 targeting bivalent covid-19 vaccine in the european union

Positive recommendation follows the recent approval of spikevax bivalent original/omicron ba.1 (mrna-1273.214), a bivalent booster vaccine targeting the omicron ba.1 subvariant, in september cambridge, ma / accesswire / october 19, 2022 / moderna, inc . (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion recommending conditional marketing authorization for mrna-1273.222 (spikevax bivalent original/omicron ba.4-5) as a booster dose for active immunization to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older, who have previously received at least a primary vaccination course against covid-19.
MRNA Ratings Summary
MRNA Quant Ranking